News > Serum Institute seeks EUA for its Covovax vaccine for 12-17 yrs age group

Serum Institute seeks EUA for its Covovax vaccine for 12-17 yrs age group

Serum Institute of India has sought emergency use authorisation from India's drug regulator for its COVID-19 vaccine Covovax for the 12 to 17 year age group.

In the application for emergency use authorisation (EUA) for the 12-17 year age group, Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII, is learnt to have stated that data show Covovax is highly efficacious, immunogenic, safe and well-tolerated in this age group.